BioSpace News Archive

Business

Mirus Bio Named a Top Workplace by the Wisconsin State Journal

Mirus Bio has been named a Top Workplace 2024 by Wisconsin State Journal Top Workplaces.

March 26, 2024
·
2 min read
Defence’s Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biotechnology company developing novel

March 26, 2024
·
4 min read
ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field

March 26, 2024
·
1 min read
Policy

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

argenx SE announced that Japan’s Ministry of Health, Labour and Welfare approved VYVGART for intravenous use in adults with primary immune thrombocytopenia.

March 26, 2024
·
8 min read
Drug Development

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Valneva SE, a specialty vaccine company, announced the initiation of a Phase 1 clinical trial to investigate the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus.

March 26, 2024
·
8 min read
Business

Echosens Appoints Dr. Victor De Lédinghen as Chief Medical Officer

Echosens announced the appointment of Victor de Lédinghen, MD PhD, as the company’s new Chief Medical Officer.

March 26, 2024
·
2 min read
Protembis Announces Completion of € 30 Million Series B Financing Round and the Addition of Keith D Dawkins MD to the Board of Directors

Protembis GmbH announced the completion of a € 30 million Series B financing round to support the enrollment of the PROTEMBO Investigational Device Exemption Pivotal Trial.

March 26, 2024
·
3 min read
Drug Development

Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2

Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, announced positive clinical data of a first in human study of Avacc 10®, an intranasal outer membrane vesicles based booster vaccine for SARS-CoV-2.

March 26, 2024
·
3 min read
Business

Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team

Laverock Therapeutics announces the appointment of Ali Elsley as Finance Director.

March 26, 2024
·
2 min read
Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432

Ubiquigent Limited announced an agreement with Debiopharm, a biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases.

March 26, 2024
·
2 min read